Core Viewpoint - A significant block trade occurred for Sichuan Zizhong Palace Pharmaceutical Co., Ltd. on November 3, with a transaction volume of 163,100 shares and a transaction value of 1.523 million yuan, reflecting a discount of 28.92% compared to the closing price of the day [2] Group 1: Block Trade Details - The block trade was executed at a price of 9.34 yuan per share, with the buyer being Tianfu Securities Co., Ltd. and the seller being Everbright Securities Co., Ltd. [2] - In the past month, the stock has seen a total of 2 block trades, amounting to a cumulative transaction value of 5.4999 million yuan [2] Group 2: Stock Performance - On the same day, the closing price of Zizhong Palace was 13.14 yuan, down by 1.50%, with a trading turnover rate of 5.54% and a total transaction amount of 82.0115 million yuan [2] - Over the last five days, the stock has increased by 6.14% [2] Group 3: Company Background - Sichuan Zizhong Palace Pharmaceutical Co., Ltd. was established on April 26, 2005, with a registered capital of 1,454.6338 million yuan [2]

Core Insights - A block trade occurred for the company Zimu Palace (stock code: 920566) on November 3, 2025, with a closing price of 13.14 yuan per share [1] - The transaction price was 9.34 yuan per share, with a total volume of 163,100 shares, amounting to 1.523 million yuan, representing a discount of 28.92% [1] Company Summary - The buying brokerage was Tianfu Securities Co., Ltd., located at Nanchong Han'an Avenue [1] - The selling brokerage was Guotai Junan Securities Co., Ltd., located at Nanchong Park Street [1]

Core Insights - The company reported a gross margin of 77.36% for the first three quarters, showing an improvement from the mid-year report, with a significant increase to 79.03% in the third quarter, indicating sustained profitability momentum [1] - The rise in gross margin reflects the company's strong technical foundation and comprehensive competitive strength in its products [1] - New products such as Celecoxib capsules and Oseltamivir phosphate capsules are rapidly gaining market traction, while prescription drugs have achieved breakthroughs in sales in Northeast China, solidifying the company's performance base [1] R&D and Production Capacity - The company has a robust R&D pipeline that supports its profitability, with clinical trials for innovative drug Maja Zizi capsules progressing steadily and other products like Vornorphan tablets nearing market launch [1] - The company is accelerating production upgrades, with the GMP expansion project in Neijiang initiated in March, leading to a significant increase in "other non-current assets" to 15.61 million, a year-on-year growth of 6565.56% [1] - The second phase of the production facility is expected to be fully completed by 2026, with partial production lines anticipated to be operational by the end of 2025, adding seven new product lines for gel formulations and soft capsules [1] Market Outlook - Open Source Securities expresses optimism regarding the company's R&D project potential and its positioning within the traditional Chinese medicine industry chain, projecting a return on equity (ROE) of 11.7% by 2026 and maintaining a "buy" rating for the company [2]

Summary of Key Points Core Viewpoint - The A-share market experienced significant block trading activity on October 10, with a total transaction volume of 2.132 billion yuan, indicating robust trading interest in select stocks [1]. Group 1: Trading Activity - A total of 71 stocks underwent block trading, with the highest transaction amounts recorded for Xinquan Co., Ltd. (319 million yuan), Guangqi Technology (296 million yuan), and Tianshan Aluminum (285 million yuan) [1]. - Among the stocks traded, 23 were sold at par value, 1 at a premium, and 47 at a discount; Tianshan Aluminum was the only stock sold at a premium with a premium rate of 0.51% [1]. - The stocks with the highest discount rates included Zizhong Temple (30.72%), Chenxi Aviation (23.13%), and Qiangrui Technology (21.83%) [1]. Group 2: Institutional Buying - The top institutional buying amounts were led by Xinquan Co., Ltd. (319 million yuan), Tianshan Aluminum (285 million yuan), and Jinlong Co., Ltd. (104 million yuan) [2]. - Other notable institutional purchases included Tianli Lithium Energy (42.32 million yuan), Shuangjie Electric (39.90 million yuan), and Juheshun (33.42 million yuan) [2]. - Additional significant transactions involved Hunan Silver (30.14 million yuan), Dongfang Yuhong (28.11 million yuan), and Baili Electric (15.50 million yuan) [2].

单位：股 | | 股东姓 | 是否为控 | | 本次 | 本次解 | 本次解除 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 股股东、 | 董事、监事、高 | 解限 | 除限售 | 限售股数 | 尚未解除 | | 序号 | 名或名 | 实际控制 | 级管理人员任职 | | | | 限售的股 | | | 称 | 人或其一 | 情况 | 售原 | 登记股 | 占公司总 | 票数量 | | | | | | 因 | 票数量 | 股本比例 | | | | | 致行动人 | | | | | | | 1 | 陈健 | 否 | 生产管理顾问 | B | 674,133 | 0.46% | 2,082,401 | | | | | （原副总经理） | | | | | | | | 合计 | | — | 674,133 | 0.46% | 2,082,401 | 注：解除限售原因： A 董事、监事、高级管理人员每年解除限售 B 离职董事、监事、高级管理人员解除限售 C 自愿限售解除限售 D 限制性股票解除限售 E 公开发行前特定主体股票解除限售上市 F 参与战 ...

根据《北京证券交易所股票上市规则》相关规定，交易的成交金额占上市 公司最近一期经审计净资产的 10%以上且超过 1,000 万元的应当予以披露；上 市公司连续 12 个月滚动发生委托理财的，以该期间最高余额为成交额，适用 上述标准。 公司本次以自有闲置资金购买理财产品的金额为人民币 1,000.00 万元， 截止目前，公司使用自有闲置资金购买理财产品的未到期余额为 20,000.00 万 元，占公司 2024 年度经审计净资产的 25.58%，达到上述披露标准，现予以披 露。 证券代码：832566 证券简称：梓橦宫 公告编号：2025-109 四川梓橦宫药业股份有限公司 关于使用自有闲置资金委托理财的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）审议情况 四川梓橦宫药业股份有限公司（以下简称"公司"）于 2024 年 9 月 26 日 召开第四届董事会第八次会议及 2024 年 10 月 18 日召开 2024 年第三次临时股 东会，审议通过了《关于使用自有闲 ...

证券代码：832566 证券简称：梓橦宫 公告编号：2025-107 公司本次以自有闲置资金购买理财产品的金额为人民币 10,000.00 万元，截 止目前，公司使用自有闲置资金购买理财产品的未到期余额为 20,000.00 万元， 占公司 2024 年度经审计净资产的 25.58%，达到上述披露标准，现予以披露。 二、 本次委托理财情况 四川梓橦宫药业股份有限公司 关于使用自有闲置资金委托理财的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）审议情况 四川梓橦宫药业股份有限公司（以下简称"公司"）于 2024 年 9 月 26 日召 开第四届董事会第八次会议及2024年10月18日召开2024年第三次临时股东会， 审议通过了《关于使用自有闲置资金购买理财产品的议案》。为提高公司资金的 使用效率，增加投资收益，在不影响公司主营业务的正常发展，并确保公司正常 经营需求的前提下，公司拟使用不超过人民币 29,000.00 万元（含）自有闲置资 金购买低风险类短期理财产 ...

Core Points - The company, Zizhong Temple, announced that it has received the acceptance notice from the National Medical Products Administration for its product, Glucosamine Sulfate Capsules, which is currently under research [2] Group 1 - The acceptance notice indicates that the company's application for domestic production and drug registration for Glucosamine Sulfate Capsules has been officially accepted [2]

证券代码：832566 证券简称：梓橦宫 公告编号：2025-106 四川梓橦宫药业股份有限公司 关于在研产品取得药品注册申请受理通知书的公告 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以 受理。受理号：CYHS2503177 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 在研产品取得阶段性成果情况 在研产品名称：硫酸氨基葡萄糖胶囊 二、 对公司的影响 硫酸氨基葡萄糖胶囊境内生产药品注册上市许可申请获得受理，有利于未来 提升公司的产品市场竞争力，同时为公司后续其他产品的研发工作积累经验，对 公司未来的经营发展具有积极意义。 三、 风险提示 近日，四川梓橦宫药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《受理通知书》，公司在研产品 硫酸氨基葡萄糖胶囊的境内生产药品注册上市许可申请获得受理。申请注册药品 的基本情况如下： 药品名称：硫酸氨基葡萄糖胶囊 规格：0.25g（以硫酸氨基葡萄糖计） 申请事项：境内生产药品注册上市许可 2 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 四川梓橦宫药业股份有限公司（以下简称"公司"）于近日收到四川省药品 监督管理局颁发的变更后的《药品生产许可证》，现就相关事项公告如下： 一、 药品生产许可证基本情况 证券代码：832566 证券简称：梓橦宫 公告编号：2025-104 四川梓橦宫药业股份有限公司 关于公司药品生产许可证变更的公告 四、备查文件目录 《药品生产许可证》 四川梓橦宫药业股份有限公司 董事会 2025 年 8 月 28 日 企业名称：四川梓橦宫药业股份有限公司 许可证编号：川 20160331 社会信用代码：91511000756614555R 分类码：AhzyBh 注册地址：内江市经济技术开发区安吉街 456 号 法定代表人：唐铣 企业负责人：李云 质量负责人：王磊 有效期至：2030 年 7 月 21 日 生产地址和生产范围：四川省内江经济技术开发区安吉街 456 号：片剂，硬 胶囊剂，散剂，搽剂，软膏剂，中药饮片，直接口服饮片，中药前处理和提取*** 以下范围仅限注册申报使 ...